_________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________

In this series, expert haemato-oncologists discuss MPNs, considering differences in patient and physician perceptions on the burden of disease, real-world evidence in MF, and how to change your approach based on a patient’s genetic mutation.
Expert advice is also provided on how to set up virtual clinics for success.

 

MF, myelofibrosis; MPN, myeloproliferative neoplasm.

UK | January 2021 | 100476
×

Ask Speakers

×

Medical Information Request

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Novartis via [email protected] or online through the pharmacovigilance intake (PVI) tool at www.report.novartis.com
If you have a question about the product, please contact Medical Information on 01276 698370 or by email at [email protected]